Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.36 |
| ▸ | HTR2B | P41595 | 7/20 | 0.36 |
| ▸ | HTR2A | P28223 | 6/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.34 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20331091 | 0.86 | CRBN (0.33) | GRM5CRBN | |
| SCHEMBL26219172 | 0.76 | CRBN (0.53) | HTR2CHTR2BHTR2ACRBNKDM5A | |
| SCHEMBL20133005 | 0.74 | CRBN (0.56) | CRBNIKZF2 | |
| SCHEMBL24654382 | 0.72 | NAMPT (0.36) | HTR2CHTR2BHTR2ACRBNIKZF2 | |
| SCHEMBL20133215 | 0.68 | HTR2C (0.53) | HTR2CHTR2BHTR2ACRBNKDM5A | |
| SCHEMBL27370438 | 0.68 | CRBN (0.38) | CRBNIKZF2 | |
| SCHEMBL21899486 | 0.68 | CRBN (0.41) | HTR2ACRBN | |
| SCHEMBL31749785 | 0.64 | GRM5 (0.46) | GRM5HRH3AOC3 | |
| SCHEMBL20133009 | 0.64 | CRBN (0.53) | CRBNIKZF2 | |
| SCHEMBL23915744 | 0.64 | CRBN (0.43) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | EGFR, ERBB2, ERBB3 | HTR2C 3717/4885HTR2B 4319/4885HTR2A 3554/4885 |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | HTR2C 3901/4885HTR2B 4277/4885HTR2A 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.